Skip to main content

Market Overview

Aerie Pharmaceuticals Shares Fall 75% On Failed Phase 3 Trial


Shares of Aerie Pharmaceuticals Inc (NASDAQ: AERI) fell 75 percent in after-hours trading following an announcement of a failed Phase 3 drug trial for Rhopressa.

Rhopressa is a “once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension,” according to the company.

According to a press release, the trial “did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily RhopressaTM compared to twice-daily timolol, the most widely used comparator in registration trials for glaucoma.”

“We expected RhopressaTM to demonstrate better performance based on the results we saw in the previous Phase 2b studies. However, if we had set the high end of the baseline range just one mmHg less, we would have demonstrated non-inferiority compared to timolol at all nine measured time points and numerical superiority at the majority of time points,” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer of Aerie.

Anido believed “RhopressaTM shows great promise at IOPs where the majority of patients are represented. Also, we believe the meaningful decrease in the number of patients that experienced efficacy loss at the lower baseline IOPs supports the potential benefit of the RhopressaTM on episcleral venous pressure.”

Aerie Pharmaceuticals recently traded at $10.40, down 70.6 percent in the after-hours session.


Related Articles (AERI)

View Comments and Join the Discussion!

Posted-In: Vicente AnidoNews Health Care After-Hours Center General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at